Anti-Inflammatory Evaluation of NLC (Nanostructured Lipid Carriers) Meloxicam In-Vivo

Moisturizing effects of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) using deionized and magnetized water by in vivo and in vitro methods

Objective(s): The present study aimed to determine and compare moisturizing and occlusion effects of different solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) using magnetized water and deionized water.Materials and Methods: SLN formulations were prepared using various lipids, including Tripalmitin, Compritol®, Pr...

Itraconazol-Loaded Nanostructured Lipid Carriers (NLC) for Pulmonary Application

Nanostructured Lipid Carriers (NLC)-Based Gel for the Topical Delivery of Aceclofenac: Preparation, Characterization, and In Vivo Evaluation

The aim of this study was to prepare nanostructured lipid carriers (NLC)-based topical gel of aceclofenac for the treatment of inflammation and allied conditions. Stearic acid as the solid lipid, oleic acid as the liquid lipid, pluronic F68 as the surfactant, and phospholipon 90G as the co-surfactant were used. NLCs were prepared by melt-emulsification, low-temperature solidification, and high-...

Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC): Occlusive Effect and Penetration Enhancement Ability

Objective: This work compares the occlusive effect and the penetration enhancement ability of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC), through in vitro skin. Methods: SLN and NLC were prepared by high shear homogenization and characterized by size, polydispersity index, zeta potential, morphology and physical stability. Occlusive effect was assessed by an in vitr...

Nanostructured Lipid Drug Carriers

solid lipid carriers – NLC. Particulate lipid matrices in the form of lipid pellets are known from the textbooks since many years, products are on the market (e. g. Mucosolvan retard, Boehringer-Ingelheim). After these lipid pellets as the first generation, P. Speiser developed so-called “lipid nanopellets for oral administration” in the middle of the eighties [1]. This system was not further d...